Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies

Table 2

Anticancer targeted therapy-related severe cutaneous adverse drug reactions from the English literature (year: 1950–2017).

Drug class	Drug	Pharmacology	References	Total (n)	Mortality	SJS	SJS/TEN	TEN
EGFR inhibitor	Afatinib	Monoclonal antibody to EGFR	[55, 56]	2	0	2	0	0
	Cetuximab	Monoclonal antibody to EGFR	[57–59]	4	1	1	1	2
	Erlotinib	TKI specific to EGFR	[60]	1	0	1	0	0
	Gefitinib	TKI specific to EGFR	[61, 62]	2	1	0	0	2
	Panitumumab	Monoclonal antibody to EGFR	[122]	1	0	1	0	0
	Vandetanib	Less specific multikinase inhibitors	[63]	2	0	0	1	1
KIT and BCR-ABL inhibitors	Imatinib	KIT, BCR-ABL, PDGFR	[64–72]	11	1	11	0	0
Antiangiogenic agents	Sorafenib	Nonselective antiangiogenesis multikinase agents	[73–76]	3	0	2	0	1
Proteasome	Bortezomib		[77]	2	1	1	0	1
CD30	Brentuximab vedotin	CD30	[78]	2	0	1	0	1
CD20	Rituximab	Monoclonal antibody to CD20	[79]	5	2	2	2	1
BRAF inhibitors	Vemurafenib	A/B/C-Raf and B-Raf (V600E)	[80]	7	1	1	0	6
			Total	42	7	23	4	15